Hubei Biocause Heilen Pharmaceutical Co., Ltd.

The company was listed on the Shenzhen Stock Exchange GEM on December 22, 2021. It was founded in 1995 and currently has more than 900 employees. The company is a post-doctoral pharmaceutical industry base in Hubei Province, a high-tech enterprise in Hubei Province, the pharmacy teaching base of Tongji Medical College of Huazhong University of Science and Technology, the fourth batch of hidden champion enterprises in Hubei Province, one of the six key insurance and supply enterprises in the fight against COVID-19 in Hubei Province in 2020, and one of the top 6 manufacturers of ibuprofen APIs in the world. It is a leading global nonsteroidal anti-inflammatory API enterprise. The company is mainly engaged in R&D, production and sales of chemical raw materials (including intermediates) and pharmaceutical products, and can provide contract R&D and production services (CDMO) according to customer needs. The company's API products are mainly non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torasemide and milinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granasetron hydrochloride. The pharmaceutical products mainly include cardiovascular preparations torasemide tablets and NSAIDs ibuprofen granules. Corporate honors: High-tech enterprises in Hubei Province in 2016 and 2021, China's top 20 CDMO enterprises in 2021, China's GMP certificate obtained in 2007, etc.